WORCESTER, Mass., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it is presenting study results at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD, www.easd.org) being held in Vienna, Austria, 29 September - 2 October, 2009 (www.easd2009.com).
